ClinicalTrials.gg
TerminatedNCT05297045Updated Nov 18, 2023

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

A Phase 2 interventional study of RGT001-075 and Placebo in Type 2 Diabetes Mellitus, sponsored by Regor Pharmaceuticals Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Regor Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Terminated due to financial constraint.

From the registry’s dates

  • Primary completion was May 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
2,594th of 2,957
17 · median 90
Started
2022
with 147 others
Phase 2
391 of 3,304
24 open now
Registered
2,633rd of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,594th largest by enrollment of the 2,957 interventional ones that give a count, is one of 148 that started in 2022, is one of 391 in phase 2, and was the 2,633rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable metformin treatment.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with type 2 diabetes that has been treated with lifestyle modification and a stable dose of metformin ≥1000 mg/day (or maximum tolerated dose) for at least 3 months at the time of Screening
  • Screening 7.0-10.5%
  • Male or female, age 18-75 years
  • Screening 24.5 - 40 kg/m2
  • Either surgically sterile, abstinent, or willing to use a highly effective method of for the entirety of the study, and not be pregnant or lactating if a woman of

Exclusion criteria

Exclusion Criteria:

  • Has received within the preceding 3 months prior to Screening, another approved or oral or injectable antidiabetic medication (including, but not limited to sulfonylureas, dipeptidyl peptidase-4 inhibitor [DPP-4i], sodium-glucose cotransport 2 inhibitors, alphaglucosidase inhibitors, meglitinides, thiazolidinediones) or insulin in addition to metformin therapy
  • Has active GI disease including acute or chronic pancreatitis, severe gastroparesis or chronic malabsorption, inflammatory bowel disease, symptomatic gallbladder or biliary disease, known unstable liver disease, a diagnosis of fibrotic nonalcoholic steatohepatitis (NASH), Gilbert's syndrome, or obvious clinical signs or symptoms of liver disease including chronic active or C, or primary biliary cirrhosis, or elevated (ALT) levels at Screening
  • Has any history of myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary therapeutic intervention, , stroke, or decompensated congestive heart failure within previous 6 months prior to Screening
  • Has an estimated (eGFR) \<30 mL/min/1.73 m2
  • Has active proliferative diabetic retinopathy or macular edema
  • Has a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid cancer
  • Has an active or untreated or has been in remission from a malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for \<5 years prior to screening
  • Has evidence of (HIV) and/or positive HIV antibodies historically or at screening
  • Has had a significant change in weight, defined as a gain or loss of at least 5% body weight in the 3 months prior to screening
  • Has been treated or plan to be treated with drugs or devices or surgery that promote weight loss within 3 months prior to screening
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Dose Group A

    Drug: RGT001-075

  • Experimental
    Dose Group B

    Drug: RGT001-075

  • Experimental
    Dose Group C

    Drug: RGT001-075

  • Experimental
    Dose Group D

    Drug: RGT001-075

  • Experimental
    Dose Group E

    Drug: RGT001-075

  • Experimental
    Dose Group F

    Drug: RGT001-075

  • Placebo comparator
    Placebo Group

    Other: Placebo

Interventions

  • Oral GLP1 Receptor Agonist

  • OtherPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Change in HbA1c from baseline to end of treatment in the modified intent-to-treat population

    Time frame: up to 16 weeks

Secondary outcomes

  1. Change in fasting plasma glucose from baseline to end of treatment in the modified intent-to-treat population

    Time frame: up to 16 weeks

  2. Change in mean body weight (absolute and %) from baseline to end of treatment in the modified intent-to-treat population

    Time frame: up to 16 weeks

  3. Change in body mass index from baseline to end of treatment in the modified intent-to-treat population

    Time frame: up to 16 weeks

  4. Change in waist circumference from baseline to end of treatment in the modified intent-to-treat population

    Time frame: up to 16 weeks

  5. Change in mean blood lipids including triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) from baseline to end of treatment in the modified intent-to-treat population

    Time frame: up to 16 weeks

  6. Percentages of patients achieving HbA1c <6.0%, <6.5%, and/or <7.0%

    Time frame: up to 16 weeks

  7. Percentages of patients achieving ≥5% and/or ≥10% greater body weight loss

    Time frame: up to 16 weeks

  8. Incidence of treatment-emergent adverse events (TEAE)s, serious adverse events (SAE)s, deaths, and adverse events (AE)s leading to study discontinuation

    Time frame: up to 16 weeks

  9. Vital signs - Systolic blood pressure (mmHg) absolute change from baseline

    Time frame: up to 16 weeks

  10. Vital signs - Diastolic blood pressure (mmHg) absolute change from baseline

    Time frame: up to 16 weeks

  11. Vital signs - Heart rate (beats/minute) absolute change from baseline

    Time frame: up to 16 weeks

  12. Vital signs - Body weight (kg) absolute and percent change from baseline

    Time frame: up to 16 weeks

  13. Safety clinical laboratories - complete blood count absolute change from baseline

    Time frame: up to 16 weeks

  14. Safety clinical laboratories - serum sodium absolute change from baseline

    Time frame: up to 16 weeks

  15. Safety clinical laboratories - serum potassium absolute change from baseline

    Time frame: up to 16 weeks

  16. Safety clinical laboratories - serum total bilirubin absolute change from baseline

    Time frame: up to 16 weeks

  17. Safety clinical laboratories - serum direct bilirubin absolute change from baseline

    Time frame: up to 16 weeks

  18. Safety clinical laboratories - serum alkaline phosphatase absolute change from baseline

    Time frame: up to 16 weeks

  19. Safety clinical laboratories - serum alanine aminotransferase absolute change from baseline

    Time frame: up to 16 weeks

  20. Safety clinical laboratories - serum aspartate aminotransferase absolute change from baseline

    Time frame: up to 16 weeks

  21. Safety clinical laboratories - serum blood urea nitrogen absolute change from baseline

    Time frame: up to 16 weeks

  22. Safety clinical laboratories - serum creatinine absolute change from baseline

    Time frame: up to 16 weeks

  23. Safety clinical laboratories - serum uric acid absolute change from baseline

    Time frame: up to 16 weeks

  24. Safety clinical laboratories - serum calcium absolute change from baseline

    Time frame: up to 16 weeks

  25. Safety clinical laboratories - serum lipase absolute change from baseline

    Time frame: up to 16 weeks

  26. Safety clinical laboratories - serum amylase absolute change from baseline

    Time frame: up to 16 weeks

  27. Safety clinical laboratories - eGFR (calculated) absolute change from baseline

    Time frame: up to 16 weeks

  28. Safety clinical laboratories - fasting serum glucose absolute change from baseline

    Time frame: up to 16 weeks

  29. Safety clinical laboratories - serum albumin absolute change from baseline

    Time frame: up to 16 weeks

  30. Safety clinical laboratories - serum total protein absolute change from baseline

    Time frame: up to 16 weeks

  31. Safety clinical laboratories - fasting serum total cholesterol absolute change from baseline

    Time frame: up to 16 weeks

  32. Safety clinical laboratories - fasting serum triglycerides absolute and percent change from baseline

    Time frame: up to 16 weeks

  33. Safety clinical laboratories - fasting serum HDL-C absolute and percent change from baseline

    Time frame: up to 16 weeks

  34. Safety clinical laboratories - fasting serum LDL-C absolute and percent change from baseline

    Time frame: up to 16 weeks

  35. Safety clinical laboratories - serum calcitonin absolute change from screening

    Time frame: up to 16 weeks

  36. ECG interval change from baseline absolute and categorical outliers >450ms

    Time frame: up to 16 weeks

  37. Proportion of patients who report AEs of Special Interest (AESI) including GI intolerability, hypoglycemia, drug hypersensitivity reactions, acute pancreatitis, thyroid C-cell hyperplasia and C-cell neoplasms, and cardiovascular (CV) events

    Time frame: up to 16 weeks

07

Study locations

1 site
  • Axon Clinical Research
    Doral, Florida 33166, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in May 2023, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2022
First posted
Mar 25, 2022
StartActual
Mar 29, 2022
Primary completionActual
May 30, 2023
CompletionActual
May 30, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05297045
Lead sponsor
Regor Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Mar 25, 2022
Start date
Mar 29, 2022
Primary completion
May 30, 2023
Completion
May 30, 2023
Last update
Nov 18, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RGT001-075

Start the discussion